Evaluation of the humoral and cellular immune response to different antigens of Corynebacterium pseudotuberculosis in Canindé goats and their potential protection against caseous lymphadenitis

Abstract

Corynebacterium pseudotuberculosis is the etiologic agent of caseous lymphadenitis, a disease that affects goats and sheep, and can cause severe economic losses. In this study, four different antigenic extracts were obtained from the attenuated strain T1, which was isolated in the state of Bahia (Brazil). Forty-four Canindé breed goats were divided in five groups, each receiving a different antigen solution and saline buffer as a control. The humoral response was monitored through the identification of specific IgG by indirect ELISA and Western Blotting, and the production of IFN-gamma was followed in order to observe the activation of cellular response. After twelve weeks of antigen inoculation, the animals were challenged with 2 x 10(5)CFU of a wild strain, also isolated in Bahia, and necropsy was performed on all animals twelve weeks afterwards. It was observed that the attenuated bacteria gave a protection of 33.3%, in addition to the weak humoral response elicited. Animals inoculated with secreted antigen associated with Freund's incomplete adjuvant and oligodeoxynucleotide containing unmethylated CpG dinucleotides (CpG ODN) showed a strong humoral response, but this inoculation could not prevent the spread of challenge bacteria in the majority of animals. These results demonstrate the immunogenic potential of the attenuated T1 strain in the development of a vaccine against caseous lymphadenitis in goats.

Development of an indirect ELISA to detect Corynebacterium pseudotuberculosis specific antibodies in sheep employing T1 strain culture supernatant as antigen

“…Consequently, the low level of specific antibodies against this enzyme in animals with no clinical signs of disease probably occurs because of the low production of exotoxin by the bacteria or poor humoral immune activation. The 70KDa antigen that was well recognized by both clinical and subclinical animals may be the 67KDa protein described by other authors (Sting et al 1998, Paule et al 2003, Moura-Costa et al 2008; it is classified as a heat shock protein (Ellis et al 1991).…”

“…The antigen was produced as already described (Moura- Costa et al 2008). Briefly, C. pseudotuberculosis T1 strain (INCQS 00512) was cultivated in BHI broth at 37°C for 48h.…”

Serological proteome analysis of Corynebacterium pseudotuberculosis isolated from different hosts reveals novel candidates for prophylactics to control caseous lymphadenitis

“…Health status of the animals was confirmed through clinical, microbiological, and serological diagnosis (Rebouças et al, 2011). Sera of individual animals in each group (CLA and control) were prepared from blood samples as described previously (Moura-Costa et al, 2008) and were pooled to be used in SERPA experiments.…”

Morel’s Disease and Caseous Lymphadenitis: a Literature Review with Special Reference to Saudi Arabia

“…Hence, various attempts have been made to obtain an attenuated live vaccine that is effective against CLA [101,102]. Experiments with live attenuated bacterial strains as vaccine models have also been performed, but the same pattern of results have been observed: evident humoral induction, varied degrees of immune protection and reduction only in the number of CLA lesions [103,104]. So, improvements are still needed to develop a vaccine model for sheep and goats.…”